Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Tyra Biosciences, Inc.NASDAQ: TYRA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $160.38M rose 7233.5% year over year, ahead of the +4048.1% change in trailing-twelve-month financing cash flow. Sequentially, it rose 3324.8% from the prior quarter. Over 3 fiscal years it compounded at +134.0% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +7233.5% holds above the trailing-twelve-month pace of +4048.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 8.1M USD
- Year-over-year change
- -96.0%
- 4-year CAGR
- -59.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.1M | -96.0% |
| FY2024 | 2024-12-31 | 202.14M | +13051.4% |
| FY2023 | 2023-12-31 | 1.54M | +143.2% |
| FY2022 | 2022-12-31 | 632K | -99.8% |
| FY2021 | 2021-12-31 | 311.35M | — |
Financing Cash Flow vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 financing cash flow of $166.3M is the 6th largest of the 11 companies compared; the peer median is $124.36M.
- Its year-over-year change of +4048.1% is the 3rd highest of 11, against a peer median of -24.1%.
- Over three fiscal years its annual growth of +134.0% compares with a peer median of +72.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $306.39M | +17210.3% | +114.1% | — | |
| LTM Mar 2026 | $251.18M | +3158.7% | +6.2% | — | |
| LTM Mar 2026 | $224.57M | +85.0% | +72.0% | 452.9% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $195.15M | -41.6% | +0.6% | — |
| LTM Jun 2026 | $179.14M | -6.5% | +434.4% | 105.4% | |
| LTM Mar 2026 | $166.3M | +4048.1% | +134.0% | — | |
| LTM Mar 2026 | $69.59M | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $50.66M | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $7.94M | -98.0% | +114.7% | 36.7% | |
| LTM Mar 2026 | $1.72M | -72.2% | -64.0% | 2.4% | |
| LTM Mar 2026 | $1.47M | -99.4% | — | — | |
| Peer median (excluding TYRA) | $124.36M | -24.1% | +72.0% | 74.9% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.89M | 10.59M | 13.53M | 22.8M | 28.01M |
| Change in Working Capital | (481K) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.49M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.97M) | (5.85M) | 6.36M | (729K) | (1.63M) |
| Other Non-Cash Items | 3K | 3K | (1.25M) | (5.88M) | (2.12M) |
| Operating Cash Flow | (23.75M) | (50.29M) | (50.14M) | (69.77M) | (95.14M) |
| Capital Expenditures | (661K) | (559K) | (770K) | (664K) | (141K) |
| Acquisitions (Net) | 16K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (143.84M) | (263.62M) | (101.25M) |
| Sales of Investments | 0 | 0 | 0 | 165.89M | 173.86M |
| Other Investing Activities | 16 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (645K) | (559K) | (144.61M) | (98.4M) | 72.46M |
| Debt Repayment | (9K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 181.22M | 632K | 1.54M | 200M | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (420K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 514K | 0 | 0 | 2.56M | 0 |
| Financing Cash Flow | 311.35M | 632K | 1.54M | 202.14M | 8.1M |
| Effect of Forex Changes | 0 | (757K) | 0 | 0 | 0 |
| Net Change in Cash | 286.96M | (50.97M) | (193.21M) | 33.96M | (14.58M) |
| Free Cash Flow | (24.41M) | (50.84M) | (50.91M) | (70.44M) | (95.28M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.